It is also important to note that although the tumour growth inhibition by cisplatin seems to be proportionally identical between shCTL and shMICU1, in the shMICU1 group four out of five animals showed negligible tumour formation upon cisplatin treatment (80% of the sample size) as compared to one out of five animals in shCTL+cisplatin group (20% of the sample size), supporting a role of MICU1 in drug resistance. This evidence concerns the gene MICU1 and neoplasm.